{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:36:28Z","timestamp":1793702188442,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>\n                      We assessed the impact of initiating intermittently scanned continuous glucose monitoring (isCGM) compared with capillary blood glucose monitoring (BGM) on HbA\n                      <jats:sub>1c<\/jats:sub>\n                      levels and hospitalisations for diabetes-related complications in adults with insulin-treated type 2 diabetes in Sweden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective comparative cohort study included adults with type 2 diabetes who had a National Diabetes Register initiation date for isCGM after 1 June 2017. Prescribed Drug Register records identified subgroups treated with multiple daily insulin injections (T2D-MDI) or basal insulin (T2D-B), with or without other glucose-lowering drugs. The National Patient Register provided data on hospitalisation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 2876 adults in the T2D-MDI group and 2292 in the T2D-B group with an isCGM index date after 1 June 2017, matched with 33,584 and 43,424 BGM control participants, respectively. The baseline-adjusted difference in the change in mean HbA\n                      <jats:sub>1c<\/jats:sub>\n                      for isCGM users vs BGM control participants in the T2D-MDI cohort was \u22123.7 mmol\/mol (\u22120.34%) at 6 months, and this was maintained at 24 months. The baseline-adjusted difference in the change in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      for isCGM users vs BGM control participants in the T2D-B cohort was \u22123.5 mmol\/mol (\u22120.32%) at 6 months, and this was also maintained at 24 months. Compared with BGM control participants, isCGM users in the T2D-MDI cohort had a significantly lower RR of admission for severe hypoglycaemia (0.51; 95% CI 0.27, 0.95), stroke (0.54; 95% CI 0.39, 0.73), acute non-fatal myocardial infarction (0.75; 95% CI 0.57, 0.99) or hospitalisation for any reason (0.84; 95% CI 0.77, 0.90). isCGM users in the T2D-B cohort had a lower RR of admission for heart failure (0.63; 95% CI 0.46, 0.87) or hospitalisation for any reason (0.76; 95% CI 0.69, 0.84).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>\n                      This study shows that Swedish adults with type 2 diabetes on insulin who are using isCGM have a significantly reduced HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and fewer hospital admissions for diabetes-related complications compared with BGM control participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-024-06289-z","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:05:41Z","timestamp":1729915541000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Intermittently scanned continuous glucose\u00a0monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies"],"prefix":"10.1007","volume":"68","author":[{"given":"David","family":"Nathanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Eeg-Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"B\u00fclow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Kyhlstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Levrat-Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bolinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"15","key":"6289_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/nejmoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 359(15):1577\u20131589. https:\/\/doi.org\/10.1056\/nejmoa0806470","journal-title":"New Engl J Med"},{"issue":"10","key":"6289_CR2","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2337\/dc20-2439","volume":"44","author":"M Lind","year":"2021","unstructured":"Lind M, Imberg H, Coleman RL, Nerman O, Holman RR (2021) Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care 44(10):2231\u20132237. https:\/\/doi.org\/10.2337\/dc20-2439","journal-title":"Diabetes Care"},{"issue":"9131","key":"6289_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/s0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837\u2013853. https:\/\/doi.org\/10.1016\/s0140-6736(98)07019-6","journal-title":"Lancet"},{"issue":"6","key":"6289_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/m16-2855","volume":"167","author":"RW Beck","year":"2017","unstructured":"Beck RW, Riddlesworth TD, Ruedy K et al (2017) Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections. Ann Intern Med 167(6):365\u2013374. https:\/\/doi.org\/10.7326\/m16-2855","journal-title":"Ann Intern Med"},{"issue":"7","key":"6289_CR5","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2337\/dc18-0166","volume":"42","author":"M Yaron","year":"2019","unstructured":"Yaron M, Roitman E, Aharon-Hananel G et al (2019) Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 42(7):1178\u20131184. https:\/\/doi.org\/10.2337\/dc18-0166","journal-title":"Diabetes Care"},{"key":"6289_CR6","doi-asserted-by":"publisher","first-page":"109172","DOI":"10.1016\/j.diabres.2021.109172","volume":"183","author":"E Bosi","year":"2022","unstructured":"Bosi E, Gregori G, Cruciani C, Irace C, Pozzilli P, Buzzetti R (2022) The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: a prospective observational cohort study. Diabetes Res Clin Pract 183:109172. https:\/\/doi.org\/10.1016\/j.diabres.2021.109172","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"6289_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G (2017) Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 8(1):55\u201373. https:\/\/doi.org\/10.1007\/s13300-016-0223-6","journal-title":"Diabetes Ther"},{"issue":"3","key":"6289_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13300-017-0255-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G (2017) Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther 8(3):573\u2013586. https:\/\/doi.org\/10.1007\/s13300-017-0255-6","journal-title":"Diabetes Ther"},{"issue":"22","key":"6289_CR9","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1001\/jama.2021.7444","volume":"325","author":"T Martens","year":"2021","unstructured":"Martens T, Beck RW, Bailey R et al (2021) Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin. JAMA 325(22):2262\u20132272. https:\/\/doi.org\/10.1001\/jama.2021.7444","journal-title":"JAMA"},{"issue":"4","key":"6289_CR10","doi-asserted-by":"publisher","first-page":"147916412110213","DOI":"10.1177\/14791641211021374","volume":"18","author":"T Elliott","year":"2021","unstructured":"Elliott T, Beca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A (2021) The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diabetes Vasc Dis Res 18(4):14791641211021374. https:\/\/doi.org\/10.1177\/14791641211021374","journal-title":"Diabetes Vasc Dis Res"},{"issue":"1","key":"6289_CR11","doi-asserted-by":"publisher","first-page":"e002590","DOI":"10.1136\/bmjdrc-2021-002590","volume":"10","author":"AL Carlson","year":"2022","unstructured":"Carlson AL, Daniel TD, DeSantis A et al (2022) Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care 10(1):e002590. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002590","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"6289_CR12","doi-asserted-by":"publisher","first-page":"bvaa118","DOI":"10.1210\/jendso\/bvaa118","volume":"4","author":"DJ Cox","year":"2020","unstructured":"Cox DJ, Banton T, Moncrief M, Conaway M, Diamond A, McCall AL (2020) Minimizing glucose excursions (GEM) with continuous glucose monitoring in type 2 diabetes: a randomized clinical trial. J Endocr Soc 4(11):bvaa118. https:\/\/doi.org\/10.1210\/jendso\/bvaa118","journal-title":"J Endocr Soc"},{"issue":"2","key":"6289_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2337\/ds20-0069","volume":"34","author":"EE Wright","year":"2021","unstructured":"Wright EE, Kerr MSD, Reyes IJ, Nabutovsky Y, Miller E (2021) Use of flash continuous glucose monitoring is associated with A1C\u00a0reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr 34(2):184\u2013189. https:\/\/doi.org\/10.2337\/ds20-0069","journal-title":"Diabetes Spectr"},{"issue":"1","key":"6289_CR14","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjdrc-2019-001115","volume":"8","author":"E Wada","year":"2020","unstructured":"Wada E, Onoue T, Kobayashi T et al (2020) Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 8(1):e001115. https:\/\/doi.org\/10.1136\/bmjdrc-2019-001115","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"6289_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2018","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD et al (2018) Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 42(3):400\u2013405. https:\/\/doi.org\/10.2337\/dc18-1444","journal-title":"Diabetes Care"},{"issue":"11","key":"6289_CR16","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.2337\/dc18-1131","volume":"41","author":"J Lu","year":"2018","unstructured":"Lu J, Ma X, Zhou J et al (2018) Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 41(11):2370\u20132376. https:\/\/doi.org\/10.2337\/dc18-1131","journal-title":"Diabetes Care"},{"key":"6289_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdi.13811","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Lu J, Shen Y et al (2022) Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients. J Diabetes Invest 13:1543\u20131550. https:\/\/doi.org\/10.1111\/jdi.13811","journal-title":"J Diabetes Invest"},{"issue":"10","key":"6289_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1089\/dia.2019.0499","volume":"22","author":"JH Yoo","year":"2020","unstructured":"Yoo JH, Choi MS, Ahn J et al (2020) Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther 22(10):768\u2013776. https:\/\/doi.org\/10.1089\/dia.2019.0499","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"6289_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/dia.2019.0251","volume":"22","author":"J Lu","year":"2020","unstructured":"Lu J, Ma X, Shen Y et al (2020) Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther 22(2):72\u201378. https:\/\/doi.org\/10.1089\/dia.2019.0251","journal-title":"Diabetes Technol Ther"},{"key":"6289_CR20","doi-asserted-by":"publisher","first-page":"1014568","DOI":"10.3389\/fendo.2022.1014568","volume":"13","author":"H Zhou","year":"2022","unstructured":"Zhou H, Wang W, Shen Q et al (2022) Time in range, assessed with continuous glucose monitoring, is associated with brachial-ankle pulse wave velocity in type 2 diabetes: a retrospective single-center analysis. Front Endocrinol 13:1014568. https:\/\/doi.org\/10.3389\/fendo.2022.1014568","journal-title":"Front Endocrinol"},{"issue":"1","key":"6289_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12933-022-01718-y","volume":"21","author":"Y Wei","year":"2022","unstructured":"Wei Y, Liu C, Liu Y et al (2022) The association between time in the glucose target range and abnormal ankle-brachial index: a cross-sectional analysis. Cardiovasc Diabetol 21(1):281. https:\/\/doi.org\/10.1186\/s12933-022-01718-y","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"6289_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12933-021-01288-5","volume":"20","author":"N Taya","year":"2021","unstructured":"Taya N, Katakami N, Mita T et al (2021) Associations of continuous glucose monitoring-assessed glucose variability with intima-media thickness and ultrasonic tissue characteristics of the carotid arteries: a cross-sectional analysis in patients with type 2 diabetes. Cardiovasc Diabetol 20(1):95. https:\/\/doi.org\/10.1186\/s12933-021-01288-5","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"6289_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2337\/dc20-1862","volume":"44","author":"J Lu","year":"2021","unstructured":"Lu J, Wang C, Shen Y et al (2021) Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care 44(2):549\u2013555. https:\/\/doi.org\/10.2337\/dc20-1862","journal-title":"Diabetes Care"},{"issue":"6","key":"6289_CR24","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.dsx.2020.09.028","volume":"14","author":"J Li","year":"2020","unstructured":"Li J, Li Y, Ma W et al (2020) Association of time in range levels with lower extremity arterial disease in patients with type 2 diabetes. Diabetes Metab Syndr 14(6):2081\u20132085. https:\/\/doi.org\/10.1016\/j.dsx.2020.09.028","journal-title":"Diabetes Metab Syndr"},{"key":"6289_CR25","unstructured":"Nationella Diabetesregistret (NDR) (2022) Annual report of the National Diabetes Register 2022. Available from https:\/\/ndr.registercentrum.se\/statistik\/arsrapporter\/p\/Skf28_I3i. Accessed April 2024"},{"issue":"11","key":"6289_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A (2009) The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24(11):659\u2013667. https:\/\/doi.org\/10.1007\/s10654-009-9350-y","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"6289_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM et al (2007) The new Swedish Prescribed Drug Register \u2013 opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidem Drug Safe 16(7):726\u2013735. https:\/\/doi.org\/10.1002\/pds.1294","journal-title":"Pharmacoepidem Drug Safe"},{"issue":"1","key":"6289_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11(1):450. https:\/\/doi.org\/10.1186\/1471-2458-11-450","journal-title":"BMC Public Health"},{"issue":"1","key":"6289_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1373\/clinchem.2003.024802","volume":"50","author":"W Hoelzel","year":"2004","unstructured":"Hoelzel W, Weykamp C, Jeppsson J-O et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50(1):166\u2013174. https:\/\/doi.org\/10.1373\/clinchem.2003.024802","journal-title":"Clin Chem"},{"key":"6289_CR30","doi-asserted-by":"publisher","unstructured":"Hanas R, John G, on behalf of the International HbA1c Consensus Committee (2010) 2010 Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care 33(8):1903\u20131904. https:\/\/doi.org\/10.2337\/dc10-0953","DOI":"10.2337\/dc10-0953"},{"issue":"7","key":"6289_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, St\u00fcrmer T, Brookhart MA, Davidian M (2011) Doubly robust estimation of causal effects. Am J Epidemiol 173(7):761\u2013767. https:\/\/doi.org\/10.1093\/aje\/kwq439","journal-title":"Am J Epidemiol"},{"issue":"3","key":"6289_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"6289_CR33","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences. Taylor & Francis, Abingdon, UK"},{"issue":"1","key":"6289_CR34","doi-asserted-by":"publisher","first-page":"147916412110674","DOI":"10.1177\/14791641211067418","volume":"20","author":"K Eeg-Olofsson","year":"2023","unstructured":"Eeg-Olofsson K, Svensson A-M, Franz\u00e9n S, Ismail HA, T\u00f6rnblom M, Levrat-Guillen F (2023) Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register. Diabetes Vasc Dis Res 20(1):14791641211067418. https:\/\/doi.org\/10.1177\/14791641211067418","journal-title":"Diabetes Vasc Dis Res"},{"issue":"11","key":"6289_CR35","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.37765\/ajmc.2021.88780","volume":"27","author":"E Miller","year":"2021","unstructured":"Miller E, Kerr MSD, Roberts GJ, Nabutovsky Y, Wright E (2021) Flash CGM associated with event reduction in nonintensive diabetes therapy. Am J Managed Care 27(11):e372\u2013e377. https:\/\/doi.org\/10.37765\/ajmc.2021.88780","journal-title":"Am J Managed Care"},{"issue":"4","key":"6289_CR36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2337\/dc22-2189","volume":"46","author":"PD Reaven","year":"2023","unstructured":"Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ (2023) Initiation of continuous glucose monitoring is linked to improved glycemic control and fewer clinical events in type 1 and type 2 diabetes in the Veterans Health Administration. Diabetes Care 46(4):854\u2013863. https:\/\/doi.org\/10.2337\/dc22-2189","journal-title":"Diabetes Care"},{"issue":"9","key":"6289_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/dia.2022.0085","volume":"24","author":"J-P Riveline","year":"2022","unstructured":"Riveline J-P, Roussel R, Vicaut E et al (2022) Reduced rate of acute diabetes events with flash glucose monitoring is sustained for two-years after initiation: extended outcomes from the RELIEF study. Diabetes Technology Ther 24(9):611\u2013618. https:\/\/doi.org\/10.1089\/dia.2022.0085","journal-title":"Diabetes Technology Ther"},{"issue":"1","key":"6289_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/dia.2022.0271","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci B, Roussel R, Levrat-Guillen F et al (2023) Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre\u00ae system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther 25(1):20\u201330. https:\/\/doi.org\/10.1089\/dia.2022.0271","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"6289_CR39","doi-asserted-by":"publisher","first-page":"bvab013","DOI":"10.1210\/jendso\/bvab013","volume":"5","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB (2021) Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc 5(4):bvab013. https:\/\/doi.org\/10.1210\/jendso\/bvab013","journal-title":"J Endocr Soc"},{"key":"6289_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fendo.2019.00536","volume":"10","author":"W Wei","year":"2019","unstructured":"Wei W, Zhao S, Fu S et al (2019) The association of hypoglycemia assessed by continuous glucose monitoring with cardiovascular outcomes and mortality in patients with type 2 diabetes. Front Endocrinol 10:536. https:\/\/doi.org\/10.3389\/fendo.2019.00536","journal-title":"Front Endocrinol"},{"key":"6289_CR41","doi-asserted-by":"publisher","first-page":"110083","DOI":"10.1016\/j.diabres.2022.110083","volume":"192","author":"Y-B Lee","year":"2022","unstructured":"Lee Y-B, Bae Y-J, Kim H et al (2022) Severe hypoglycemia and risk of hospitalization for heart failure in adults with diabetes treated with oral medications with or without insulin: a population-based study. Diabetes Res Clin Pract 192:110083. https:\/\/doi.org\/10.1016\/j.diabres.2022.110083","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06289-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06289-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T02:02:20Z","timestamp":1734746540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06289-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6289"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06289-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editorial assistance in the preparation of this article was provided by R. Brines of Bite Medical Consulting, who collated author drafts and changes, and proofread successive drafts of the manuscript prior to submission. Financial support for this assistance was provided by Abbott Diabetes Care. Parts of this study were presented at the 59th Annual Meeting of the EASD, Hamburg, Germany, 2\u20136 October 2023.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data not presented in the analysis are available on request from the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Open access funding provided by Karolinska Institute. Financial support for this study was provided by Abbott Diabetes Care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DN received honoraria from Abbott for the work within this study. KE-O has received fees for lecturing and\/or honoraria for consulting from Sanofi, Novo Nordisk, Eli Lilly and Abbot Diabetes Care. TS has received compensation for serving on scientific advisory boards and honoraria for consultancy from Biogen, as well as speaker honoraria from Novartis. MK is employed by Synergus RWE, which received reimbursement from Abbott to perform the analysis. FL-G is an employee of Abbott Diabetes Care. JB has received honoraria for consulting and\/or lecture fees from Abbott Diabetes Care, MannKind Corporation, Nanexa, Nordic InfuCare, Novo Nordisk and Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"DN, KE-O and JB are the guarantors of this work, and, as such, had full access to all the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the methodology, analyses and manuscript writing. All authors gave their approval for this version to be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}